| Platinum Resistance Markers | ||||
|---|---|---|---|---|
| Marker | Name | Biological Role | Evidence | References |
| ERCC1 | Excision repair complementation group 1 | DNA repair (nucleotide-excision repair pathway) | High protein expression correlates with reduced response and poor outcome following platinum-based chemotherapy in ovarian cancer | Platinum Resistance: ERCC1 References |
| BRCA1 | Breast cancer 1 | DNA repair (Homologous recombination-- double strand break repair) | High mRNA expression correlates with reduced survival of ovarian cancer patients treated with platinum | Platinum Resistance: BRCA1 References |
| BcL-xL | BCL2-like 1 | Anti-apoptotic protein | High protein expression is associated with chemo-resistance and recurrent disease following platinum treatment in ovarian cancer patients | Platinum Resistance: Bcl-xL References |
| Bcl-2 | B-cell CLL/lymphoma 2 | Outer mitochondrial membrane protein that blocks apoptotic cell death | High protein expression is associated with resistance to platinum treatment and poor prognosis in ovarian cancer patients; p53 status and combination therapy partner (e.g., cyclophosphamide) may alter predictive ability | Platinum Resistance: Bcl-2 References |
| MT | Metallothionein | Protein reduces toxicity associated with heavy metals and divalent cations | High protein expression is correlated with poor outcome following platinum-based chemotherapy in ovarian cancer | Platinum Resistance: MT References |
